Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026

Core Insights - Anavex Life Sciences Corp. will release its financial results for the first quarter of fiscal 2026 on February 9, 2026, at 8:30 am ET [1] - A conference call will be held on the same day to review financial results and discuss recent corporate developments, followed by a Q&A session [2] Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for various CNS disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, and Rett syndrome [4] - The company's lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and has shown potential in treating other CNS disorders [4] - ANAVEX®3-71 is another promising drug candidate targeting SIGMAR1 and M1 muscarinic receptors, demonstrating disease-modifying activity against Alzheimer's disease in preclinical trials [4]